(RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept.

We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...

Biogen (NASDAQ:BIIB – Free Report) had its price target boosted by Robert W. Baird from $294.00 to $300.00 in a research ...

OPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen's ...

In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and ...

RFK Jr.’s main claim to fame, apart from his ancestry, is from saying crazy things about vaccines. As has ...

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS ...

Shares of CVS Health (NYSE:CVS) rose 2.8% in premarket trading on Monday following a report from the Wall Street Journal that ...

HCW Biologics entered into License, Research and Co-Development Agreement HCW Biologics to receive upfront payment of $7 ...

Investing.com - The U.S. dollar slips slightly from the recently reached one-year high at the start of a week that is light ...

A search for a solution to the crisis in Haiti is growing more urgent as gangs gain territory and thousands more flee their homes. By Frances Robles With two months left in office, the president ...